期刊
CANCERS
卷 14, 期 20, 页码 -出版社
MDPI
DOI: 10.3390/cancers14205121
关键词
extracellular vesicles; microbiota; anti-PD therapy; cancer
类别
资金
- Academy of Finland [328768, 299749]
- Academy of Finland (AKA) [328768, 299749, 299749, 328768] Funding Source: Academy of Finland (AKA)
Immune checkpoint inhibitors (ICI) targeting PD-1/PD-L1 have shown promise as contemporary treatments for cancer. This review discusses the potential role of microbiota-derived extracellular vesicles in improving anti-PD-1/PD-L1 therapy outcomes. Bacterial extracellular vesicles have the ability to cross barriers and modify the tumor microenvironment, offering new therapeutic avenues for cancer treatment.
Simple Summary Immune checkpoint inhibitors (ICI) targeting PD-1/PD-L1 have emerged as contemporary treatments for a variety of cancers. However, the efficacy of antibody-based ICIs could be further enhanced. Microbiota have been demonstrated to be among the vital factors governing cancer progression and response to therapy in patients. Bacteria secrete extracellular vesicles carrying bioactive metabolites within their cargo that can cross physiological barriers, selectively accumulate near tumor cells, and alter the tumor microenvironment. Extracellular vesicles, particularly those derived from bacteria, could thus be of promising assistance in refining the treatment outcomes for anti-PD-1/PD-L1 therapy. The potentiality of microbiota-derived extracellular vesicles in improving the currently used treatments and presenting new therapeutic avenues for cancer has been featured in this review. Cancer is a deadly disease worldwide. In light of the requisite of convincing therapeutic methods for cancer, immune checkpoint inhibition methods such as anti-PD-1/PD-L1 therapy appear promising. Human microbiota have been exhibited to regulate susceptibility to cancer as well as the response to anti-PD-1/PD-L1 therapy. However, the probable contribution of bacterial extracellular vesicles (bEVs) in cancer pathophysiology and treatment has not been investigated much. bEVs illustrate the ability to cross physiological barriers, assemble around the tumor cells, and likely modify the tumor microenvironment (EVs). This systematic review emphasizes the correlation between cancer-associated extracellular vesicles, particularly bEVs and the efficacy of anti-PD-1/PD-L1 therapy. The clinical and pharmacological prospective of bEVs in revamping the contemporary treatments for cancer has been further discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据